ArticleAntimicrobial agents and chemotherapy2016
Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05739825 (Assessment Of Changes In Gut Microbiota Of Patients With Recurrent Clostridioides Difficile Infection After Fecal Microbiota Transplantation), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment Of Changes In Gut Microbiota Of Patients With Recurrent Clostridioides Difficile Infection After Fecal Microbiota Transplantation: Prospective Study
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Article
- Antibiotic therapy for severe bacterial infections.Intensive care medicine · 2025Review
- The role of Frailty Index Laboratory in predicting clinical outcomes in patients withJAC-antimicrobial resistance · 2025Article
- Article
- Decreased Antimicrobial Resistance Gene Richness Following Fecal Microbiota, Live-jslm (REBYOTA®) Administration: Post Hoc Analysis of PUNCH CD3.Open forum infectious diseases · 2025Article
- Review
- Fecal Microbiota Transplantation as Emerging Treatment in European Countries 2.0.Advances in experimental medicine and biology · 2024Review
- Increased Incidence and Risk of Septicemia and Urinary Tract Infection AfterOpen forum infectious diseases · 2023Article
- The burden of CDI in the United States: a multifactorial challenge.BMC infectious diseases · 2023Review
- Fidaxomicin for the Treatment ofAntibiotics (Basel, Switzerland) · 2022Review
- Long-term antibiotic exposure promotes mortality after systemic fungal infection by driving lymphocyte dysfunction and systemic escape of commensal bacteria.Cell host & microbe · 2022Article
- Clinical Impact of COVID-19 on Multi-Drug-Resistant Gram-Negative Bacilli Bloodstream Infections in an Intensive Care Unit Setting: Two Pandemics Compared.Antibiotics (Basel, Switzerland) · 2022Article
- Concurrent and Subsequent Co-Infections ofMicroorganisms · 2022Review
- Oral Vancomycin Prophylaxis for Primary and Secondary Prevention ofAntibiotics (Basel, Switzerland) · 2022Review
- Clinical burden of recurrentAntimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
- An Atypical Case of MonomicrobialFrontiers in cellular and infection microbiology · 2022Article
- Gut microbiota and microbiota-based therapies forFrontiers in medicine · 2022Review
- Detection of Pathogenic Bacteria From Septic Patients Using 16S Ribosomal RNA Gene-Targeted Metagenomic Sequencing.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Clinical complications in patients with primary and recurrentSAGE open medicine · 2021Article
- Editorial: Spotlight on the Relationship Between Sepsis and Infection: From Mechanisms to Therapy.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We determined the incidence, risk factors, and outcomes of bloodstream infections (BSI) subsequent to Clostridium difficile infection (CDI). We performed a retrospective study of all patients with definite diagnosis of CDI admitted from January 2014 to December 2014 in two large hospitals in Rome. Two groups of patients were analyzed: those with CDI and subsequent BSI (CDI/BSI(+)) and those with CDI and no evidence of primary BSI (CDI/BSI(-)). Data about clinical features, microbiology, treatments, and mortality were obtained. Overall, 393 cases of CDI were included in the final analysis: 72 developed a primary nosocomial BSI, while 321 had CDI without microbiological and clinical evidence of BSI. Etiologic agents of BSI were Candida species (47.3%), Enterobacteriaceae (19.4%), enterococci (13.9%), and mixed infections (19.4%). In multivariate analysis, ribotype 027 status (odds ratio [OR], 6.5), CDI recurrence (OR, 5.5), severe CDI infection (OR, 8.3), and oral vancomycin at >500 mg/day (OR, 3.1) were recognized as factors independently associated with the development of nosocomial BSI. Thirty-day mortality from CDI diagnosis was higher for patients of the CDI/BSI(+) group than for the controls (38.9 versus 13.1%; P < 0.001). Among patients of the CDI/BSI(+) group, mortality attributable to primary BSI was as high as 57%. Our findings suggest that severe CDI is complicated by the development of nosocomial BSI. Candida species and enteric bacteria appear to be the leading causative pathogens and are associated with poor outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.